- Podcast: Non-binding Guidance: The Defense Production Act and the COVID-19 Pandemic (May 27, 2021)
- Attorneys Examine FDA Enforcement Implications of U.S. Supreme Court Decision on Restitution and Disgorgement (May 6, 2021)
- New Laws Narrow the Scope of Market Exclusivity and Seek to Increase Awareness of Biosimilars (April 30, 2021)
- Event: Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations (March 25, 2021)
- Podcast: Non-binding Guidance: FDA Regulatory Developments in AI and Machine Learning
(March 4, 2021)
- FDA Publishes Action Plan for Oversight of Artificial Intelligence/Machine Learning-Based Medical Software
(February 9, 2021)
- 2020 Enforcement Review: FDA-Regulated Medical Products and Food Safety (January 28, 2021)
- The 2020 Election and Life Sciences (December 1, 2020)
- In Law360, Attorneys Examine Change in FDA's Review Priorities for COVID-19 Lab-Developed Tests (October 22, 2020)
- In Bloomberg Law, Greg Levine Evaluates FDA Plans for Permanent COVID-19 Test Authorization (October 20, 2020)
Cookie Settings
